Holen Sie sich die Stockscreener-App
2.76
1.08%
-0.03
Handel nachbörslich:
2.76
Black Diamond Therapeutics Inc Aktie (BDTX) Neueste Nachrichten
Price action breakdown for Black Diamond Therapeutics Inc.Insider Buying & Daily Entry Point Trade Alerts - Newser
Black Diamond (BDTX) Q2 Loss Narrows 47% - AOL.com
Is Black Diamond Therapeutics Inc. Forming a Consolidation BaseJuly 2025 Sector Moves & Free Real-Time Market Sentiment Alerts - newsyoung.net
Analysts Offer Predictions for BDTX FY2026 Earnings - Defense World
What moving averages say about Black Diamond Therapeutics Inc.Earnings Risk Report & Real-Time Volume Spike Alerts - Newser
Will Breakout in Black Diamond Therapeutics Inc. Sustain Through Next Week2025 Institutional Moves & Consistent Profit Alerts - metal.it
Machine Learning Models Forecast Black Diamond Therapeutics Inc. Uptick2025 Investor Takeaways & Precise Buy Zone Identification - metal.it
HC Wainwright Has Lowered Expectations for Black Diamond Therapeutics (NASDAQ:BDTX) Stock Price - Defense World
Chart based analysis of Black Diamond Therapeutics Inc. trendsBuy Zone Strategy with Pattern Recognition - Newser
Top Risks to Consider Before Buying Black Diamond Therapeutics Inc. StockInstitutional Holding Behavior Pattern Analysis - Newser
Black Diamond Therapeutics Reports Strong Financial Turnaround - TipRanks
Black Diamond Therapeutics, Inc. (BDTX) Rated Outperform as Lead Drug Shows Promise - MSN
What makes Black Diamond Therapeutics Inc. stock price move sharplyDaily Pattern Analysis with Return Forecast - Newser
H.C. Wainwright Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Cuts Target Price to $10 - 富途牛牛
H.C. Wainwright lowers Black Diamond Therapeutics stock price target on delayed launch - Investing.com Canada
Published on: 2025-08-11 06:28:53 - Newser
Black Diamond:HC Wainwright lowers PT to $10 from $12, maintains Buy rating. - AInvest
News impact scoring models applied to Black Diamond Therapeutics Inc.Fundamental Forecast for Undervalued Stocks - Newser
When is the best time to exit Black Diamond Therapeutics Inc.Momentum Trend Signal Weekly Recap Summary - Newser
Is Black Diamond Therapeutics Inc. a Top Dividend Stock to Watch in 2025Free Weekly Hot Picks With Buy Confidence - Newser
Black Diamond Therapeutics (NASDAQ:BDTX) Downgraded by Wall Street Zen to “Hold” - Defense World
Black Diamond Therapeutics, Inc.'s (NASDAQ:BDTX) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects? - Yahoo Finance
Black Diamond Therapeutics Reports Q2 Earnings with $45.98M Net Income and $70M Upfront Payment from Servier Agreement - AInvest
Black Diamond Therapeutics Maintains Buy Rating with $11 Price Target - AInvest
Historical volatility pattern of Black Diamond Therapeutics Inc. visualizedFree Daily Chart Pattern Stock Forecast - Newser
Black Diamond Therapeutics shares rise 1.75% premarket after reporting a narrower Q2 net loss and exploring partnerships for silevertinib development. - AInvest
Black Diamond Therapeutics Slims Losses And Stays Flush With Cash - Finimize
Black Diamond: Q2 Earnings Snapshot - Stamford Advocate
Black Diamond Therapeutics: Navigating Turbulent Waters with Strategic Precision - AInvest
Black Diamond Therapeutics Cuts Losses And Eyes Silevertinib Growth - Finimize
Black Diamond Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Black Diamond Therapeutics Reports Q2 2025 Financial Results: Net Loss Down 47%, Cash Reserves Reach $142.8 Million - AInvest
Black Diamond Therapeutics Q2 Loss Narrower Than ExpectedNews and Statistics - IndexBox
Black Diamond Therapeutics Q2 eps $-0.19 - MarketScreener
Black Diamond (BDTX) Q2 Loss Narrows 47% - The Motley Fool
Black Diamond Therapeutics Completes Enrollment in Phase 2 Trial of Silevertinib for Non-Classical EGFRm NSCLC - Quiver Quantitative
Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Black Diamond's Lung Cancer Drug Trial Hits Key Milestone, Major Data Release Coming in Q4 - Stock Titan
Black Diamond Therapeutics, Inc. SEC 10-Q Report - TradingView
Will Black Diamond Therapeutics Inc. Stock Benefit from AI and Green Energy TrendsFree Daily Top Performing Stock Insights - Newser
Why Black Diamond Therapeutics Inc. stock attracts strong analyst attentionFree Investment Playbook for Growing Markets - Newser
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Given Average Rating of “Buy” by Brokerages - Defense World
Is Black Diamond Therapeutics Inc. stock ready for a breakoutHigh Return Idea With Technical Filter - Newser
0.41%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):